Parallel Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Sell
75,984
-2,490
-3% -$349K 0.19% 80
2025
Q4
$9.63M Buy
78,474
+4,004
+5% +$487K 0.18% 86
2025
Q3
$8.27M Buy
74,470
+39,239
+111% +$4.46M 0.15% 101
2025
Q2
$3.91M Buy
35,231
+1,067
+3% +$114K 0.08% 175
2025
Q1
$3.83M Sell
34,164
-2,876
-8% -$297K 0.09% 170
2024
Q4
$3.42M Sell
37,040
-2,258
-6% -$203K 0.08% 187
2024
Q3
$3.29M Sell
39,298
-18,825
-32% -$1.44M 0.08% 193
2024
Q2
$3.99M Buy
58,123
+12,349
+27% +$824K 0.1% 152
2024
Q1
$3.35M Buy
45,774
+2,438
+6% +$187K 0.09% 167
2023
Q4
$3.51M Buy
43,336
+207
+0.5% +$16.1K 0.1% 151
2023
Q3
$3.23M Sell
43,129
-1,421
-3% -$109K 0.11% 149
2023
Q2
$3.43M Buy
44,550
+404
+0.9% +$32.2K 0.11% 148
2023
Q1
$3.66M Buy
44,146
+1,908
+5% +$158K 0.12% 143
2022
Q4
$3.63M Sell
42,238
-2,389
-5% -$189K 0.16% 99
2022
Q3
$2.75M Buy
44,627
+7,680
+21% +$484K 0.13% 114
2022
Q2
$2.28M Buy
36,947
+1,488
+4% +$92.1K 0.1% 131
2022
Q1
$2.12M Buy
35,459
+2,205
+7% +$141K 0.08% 159
2021
Q4
$2.42M Buy
33,254
+2,255
+7% +$155K 0.09% 149
2021
Q3
$2.17M Buy
30,999
+1,657
+6% +$116K 0.09% 161
2021
Q2
$2.02M Buy
29,342
+2,335
+9% +$156K 0.09% 161
2021
Q1
$1.75M Buy
27,007
+821
+3% +$52.9K 0.08% 173
2020
Q4
$1.53M Sell
26,186
-450
-2% -$27.2K 0.08% 166
2020
Q3
$1.68M Sell
26,636
-1,801
-6% -$125K 0.1% 145
2020
Q2
$2.19M Buy
28,437
+363
+1% +$27.8K 0.14% 111
2020
Q1
$2.1M Buy
28,074
+3,005
+12% +$208K 0.17% 96
2019
Q4
$1.63M Sell
25,069
-1,276
-5% -$83.1K 0.12% 133
2019
Q3
$1.67M Buy
26,345
+150
+0.6% +$9.8K 0.14% 122
2019
Q2
$1.77M Buy
26,195
+607
+2% +$39.9K 0.17% 104
2019
Q1
$1.66M Sell
25,588
-116
-0.5% -$7.71K 0.19% 99
2018
Q4
$1.61M Sell
25,704
-6,138
-19% -$429K 0.22% 84
2018
Q3
$2.46M Buy
31,842
+25,900
+436% +$1.96M 0.31% 60
2018
Q2
$420K Sell
5,942
-1,173
-16% -$82.8K 0.06% 208
2018
Q1
$536K Sell
7,115
-178
-2% -$14.2K 0.08% 174
2017
Q4
$522K Buy
7,293
+208
+3% +$15.8K 0.09% 166
2017
Q3
$516K Buy
7,085
+147
+2% +$11.2K 0.09% 161
2017
Q2
$528K Buy
6,938
+2,014
+41% +$134K 0.1% 156
2017
Q1
$331K Sell
4,924
-4,244
-46% -$298K 0.07% 207
2016
Q4
$657K Buy
+9,168
New +$681K 0.15% 113

Other funds holding GILD

Parallel Advisors's GILD Position: Q1 2026 in Review

Parallel Advisors reduced its Gilead Sciences (GILD) stake by 3.2% in Q1 2026, selling an estimated $349K and leaving 75,984 shares worth $10.6M. The position accounts for 0.19% of the portfolio, ranked #80.

Parallel Advisors first reported a position in GILD in Q4 2016 and has held it in 38 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Parallel Advisors held 75,984 shares of Gilead Sciences worth $10.6M as of Q1 2026.
  • Parallel Advisors sold 2,490 Gilead Sciences shares in Q1 2026, an estimated $349K.
  • Gilead Sciences made up 0.19% of Parallel Advisors's portfolio in Q1 2026, its #80 holding.
  • Parallel Advisors first reported a position in Gilead Sciences in Q4 2016 and has held it in 38 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.